Hugel, Inc.
KOE: 145020.KQ0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Carrie C. Strom
- Employees
- 594
- Headquarters
- Chuncheon-si, South Korea
- IPO year
- 2015
- Market cap
- ₩3.1T
- Website
- https://www.hugel.co.kr
Loading 145020…
Loading profile data…Frequently asked questions about 145020
What does Hugel, Inc. (145020.KQ) do?
Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally. The company offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator...
Where does 145020.KQ trade?
Hugel, Inc. (145020.KQ) trades on the KOSDAQ.
What sector is 145020.KQ in?
Hugel, Inc. (145020.KQ) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Hugel, Inc.?
Carrie C. Strom is the chief executive officer of Hugel, Inc. (145020.KQ).
Where is Hugel, Inc. headquartered?
Hugel, Inc. is headquartered in South Korea.
Does 145020.KQ pay a dividend?
Hugel, Inc. (145020.KQ) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 145020.KQ go public?
Hugel, Inc. (145020.KQ) completed its initial public offering in 2015.